Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. News Desk 2018 Message Board

New Elsevier Book Examines Complex Mechanisms Rela

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 617763
(Total Views: 165)
Posted On: 04/05/2017 5:00:02 AM
Avatar
Posted By: News Desk 2018
New Elsevier Book Examines Complex Mechanisms Relating to Cardiac Diseases from Pathophysiological and Clinical Viewpoints

CAMBRIDGE, MA --(Marketwired - April 05, 2017) - Elsevier , the information analytics company specializing in science and health, today announced the publication of The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic Approaches , edited by Udi Nussinovitch. A state-of-the-art collection of current information regarding medical cardiac complications of prevalent rheumatic, autoimmune and inflammatory diseases, the book resulted from an extended coordinated collaboration of 154 distinguished scientists from 31 countries around the globe. Elsevier also announced the publication of another cardiology book.

The Heart in Rheumatic, Autoimmune and Inflammatory Diseases focuses on aspects of pathophysiological processes, clinical presentations, screening tests, prognostic implications and novel therapeutic approaches. It presents up-to-date 'level of evidence' and 'strengths of recommendations' for suggested therapies, and reviews all randomized clinical trials, meta-analyses and other supporting published clinical findings.

Learn more about the pathophysiology of autoimmunity in this sample chapter.

Dr Nussinovitch carries out his clinical work at the Rambam Healthcare Campus, a tertiary medical facility and leading referral center in northern Israel, academically affiliated to the Technion Institute of Technology, Israel. He has dedicated his research primarily to cardiac autoimmunity and autoinflammation, cardiac manifestations of systemic diseases, cell- and gene-based cardiac therapies, and the modulation of the cardiac electrophysiologic substrate for therapeutic purposes. Dr. Nussinovitch has published articles in leading rheumatologic and cardiovascular journals, as well as several chapters in scientific textbooks, mostly dealing with cardiac autoimmunity. He has received multiple awards and serves as a reviewer for prestigious rheumatologic and cardiac journals.

The two new cardiology titles are:

  • The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic Approaches , edited by Udi Nussinovitch
  • Matrix Metalloproteinses and Tissue Remodeling in Health and Disease: Cardiovascular Remodeling , edited by Raouf Khalil

In order to meet content needs in cardiology, Elsevier uses proprietary tools to identify the gaps in coverage of the topics. Editorial teams strategically fill those gaps with content written by key influencers in the field, giving students, faculty and researchers the content they need to answer challenging questions and improve outcomes. These new books, which will educate the next generation of cardiologists, and provide critical foundational content for information professionals, are key examples of how Elsevier is enabling science to drive innovation.

Note for Editors Only credentialed media can request eBook review copies by email, sciencereviewcopies@elsevier.com

About Elsevier Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect , Scopus , ClinicalKey and Sherpath . Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell , more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy . Elsevier is part of RELX Group , a world-leading provider of information and analytics to professionals and business customers, in a wide range of industries. www.elsevier.com

Image Available: http://www.marketwire.com/library/MwGo/2017/4...d5b10f.jpg

Media Contact Pam Foote Publicity Contact, Science & Technology Books, Elsevier footep@reedelsevier.com +1-978-837-8182



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us